213 related articles for article (PubMed ID: 32923626)
1. Immunotherapy via PD-L1-presenting biomaterials leads to long-term islet graft survival.
Coronel MM; Martin KE; Hunckler MD; Barber G; O'Neill EB; Medina JD; Opri E; McClain CA; Batra L; Weaver JD; Lim HS; Qiu P; Botchwey EA; Yolcu ES; Shirwan H; García AJ
Sci Adv; 2020 Aug; 6(35):eaba5573. PubMed ID: 32923626
[TBL] [Abstract][Full Text] [Related]
2. Localized Immunomodulation with PD-L1 Results in Sustained Survival and Function of Allogeneic Islets without Chronic Immunosuppression.
Batra L; Shrestha P; Zhao H; Woodward KB; Togay A; Tan M; Grimany-Nuno O; Malik MT; Coronel MM; García AJ; Shirwan H; Yolcu ES
J Immunol; 2020 May; 204(10):2840-2851. PubMed ID: 32253240
[TBL] [Abstract][Full Text] [Related]
3. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
[TBL] [Abstract][Full Text] [Related]
4. Delayed graft rejection in autoimmune islet transplantation via biomaterial immunotherapy.
Coronel MM; Linderman SW; Martin KE; Hunckler MD; Medina JD; Barber G; Riley K; Yolcu ES; Shirwan H; García AJ
Am J Transplant; 2023 Nov; 23(11):1709-1722. PubMed ID: 37543091
[TBL] [Abstract][Full Text] [Related]
5. Local immunomodulation Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance.
Headen DM; Woodward KB; Coronel MM; Shrestha P; Weaver JD; Zhao H; Tan M; Hunckler MD; Bowen WS; Johnson CT; Shea L; Yolcu ES; García AJ; Shirwan H
Nat Mater; 2018 Aug; 17(8):732-739. PubMed ID: 29867165
[TBL] [Abstract][Full Text] [Related]
6. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
7. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.
Fiorina P; Jurewicz M; Vergani A; Petrelli A; Carvello M; D'Addio F; Godwin JG; Law K; Wu E; Tian Z; Thoma G; Kovarik J; La Rosa S; Capella C; Rodig S; Zerwes HG; Sayegh MH; Abdi R
J Immunol; 2011 Jan; 186(1):121-31. PubMed ID: 21131428
[TBL] [Abstract][Full Text] [Related]
8. The impact of cell surface PEGylation and short-course immunotherapy on islet graft survival in an allogeneic murine model.
Giraldo JA; Molano RD; Rengifo HR; Fotino C; Gattás-Asfura KM; Pileggi A; Stabler CL
Acta Biomater; 2017 Feb; 49():272-283. PubMed ID: 27915019
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-1 targeting can promote allograft survival.
Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 costimulatory pathway-induced mouse islet transplantation immune tolerance.
Li T; Ma R; Zhu JY; Wang FS; Huang L; Leng XS
Transplant Proc; 2015; 47(1):165-70. PubMed ID: 25645798
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.
Yolcu ES; Zhao H; Bandura-Morgan L; Lacelle C; Woodward KB; Askenasy N; Shirwan H
J Immunol; 2011 Dec; 187(11):5901-9. PubMed ID: 22068235
[TBL] [Abstract][Full Text] [Related]
13. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the OX40/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection.
Li T; Ma R; Zhu J; Wang F; Huang L; Leng X
Chin Med J (Engl); 2014; 127(14):2686-92. PubMed ID: 25043090
[TBL] [Abstract][Full Text] [Related]
16. Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege.
Cheng X; Dai H; Wan N; Moore Y; Vankayalapati R; Dai Z
Transplantation; 2009 Jun; 87(12):1778-86. PubMed ID: 19543053
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Deficiency within Islets Reduces Allograft Survival in Mice.
Ma D; Duan W; Li Y; Wang Z; Li S; Gong N; Chen G; Chen Z; Wan C; Yang J
PLoS One; 2016; 11(3):e0152087. PubMed ID: 26990974
[TBL] [Abstract][Full Text] [Related]
19. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
Fife BT; Pauken KE; Eagar TN; Obu T; Wu J; Tang Q; Azuma M; Krummel MF; Bluestone JA
Nat Immunol; 2009 Nov; 10(11):1185-92. PubMed ID: 19783989
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
